Based on these pharmacological strategies triggered by BNP or NT-proBNP levels above the risk threshold, the studies PONTIAC43 and STOP-HF42 suggested reducing the risk for HF hospitalization and mortality. This evidence concerns the gene NPPB and hydrops fetalis.